This paper provides a comprehensive overview of late-onset Alzheimer's disease (LOAD), examining its epidemiology, etiology, risk factors, symptom progression, and pathophysiology. The paper reviews findings from genetic studies linking LOAD to candidate genes such as GAB2, LOC651924, and mitochondrial haplogroups, as well as research on white matter damage patterns distinguishing early- and late-onset patients. The roles of amyloid oligomers, proinflammatory cytokines, and calcium-sensing receptors in neurodegeneration are discussed. Current pharmacological treatments — including cholinesterase inhibitors and memantine — are evaluated, and future research directions, including the relationship between proinflammatory genotypes, systemic inflammation, and disease-modifying therapies, are identified.
This study guide is drawn from PaperDue's library of 130,000+ paper examples across 47 subjects.
The paper exemplifies evidence synthesis across disciplines — integrating findings from genetics (candidate gene studies, mitochondrial haplogroup research), neuropathology (white matter imaging), and pharmacology into a coherent narrative about a single disease. Rather than summarizing each study in isolation, the author weaves them together to show how different lines of evidence converge on or complicate the same pathophysiological picture.
The paper follows a classic biomedical review structure: it opens with definitional and epidemiological context, proceeds through etiology, risk factors, and staged symptomatology, then deepens into cellular and genetic pathogenesis before closing with clinical pharmacology and a future research outlook. Each section is labeled, making the progression transparent and easy to navigate. This structure is well suited to a pathophysiology review at the graduate level.
Alzheimer's disease (AD) is the most common form of dementia; it is both progressive and incurable. Early-onset Alzheimer's disease is defined by the appearance of symptoms before the age of 65 (Canu et al., 2010). Compared to late-onset AD patients, early-onset AD patients show a more rapid cognitive and clinical decline, along with earlier impairment of a multidomain nature that includes language, executive functions, and visuospatial abilities, although memory deficits may be less severe (Canu et al., 2010). Early-onset AD is generally considered to be a more aggressive form of the disease.
It is estimated that 5.3 million Americans have AD, with 10 to 13% of people older than 65 affected (Buckley & Schub, 2012). Incidence rises to 40% in populations older than 85 years of age (Buckley & Schub, 2012). The prevalence of AD grows higher with advancing age, a factor that drives estimates of new diagnoses to roughly one million added each year for the next 40 years or so (Buckley & Schub, 2012). Practically speaking, 11 to 15 million Americans are expected to have AD by the year 2050 (Buckley & Schub, 2012). The incidence rate shows approximately 10% of cases as inherited and about 90% as sporadic, or non-inherited (Buckley & Schub, 2012).
Institutionalization of patients is common. The association between years following diagnosis and institutionalization rates is as follows: 20% of patients are institutionalized one year after diagnosis, 50% at five years, and close to 90% at eight years (Buckley & Schub, 2012).
Alzheimer's disease is evidenced by cognitive deficits in speech and language, memory, and motor skills (Buckley & Schub, 2012). Patients who exhibit this constellation of diminished day-to-day functioning experience significant problems in the social and occupational aspects of life (Buckley & Schub, 2012). The accompanying ramifications for family, friends, and community members are substantive (Buckley & Schub, 2012). The disease progresses differently across patients; however, neurodegenerative complications inevitably make the disease fatal (Buckley & Schub, 2012).
The primary risk factor for AD is advanced age — a risk that doubles for every five years after a person reaches age 65 (Buckley & Schub, 2012). Higher-than-normal risk is also associated with having a first-degree relative with AD. Other conditions linked to increased risk include Down syndrome, head trauma, and exposure to certain environmental contaminants such as metals, toxins, and infectious agents (Buckley & Schub, 2012). Alzheimer's has further been associated with decreased estrogen levels, cardiovascular disease, and cardiovascular risk factors such as obesity, hypertension, dyslipidemia, and insulin resistance, as well as depression and lifestyle factors including smoking, poor diet, lack of exercise, and alcohol consumption (Buckley & Schub, 2012).
There is some evidence that memory functions are under strong genetic influence in older people regardless of AD status, suggesting that variability in memory function can only partly be attributed to the APOE genotype (Wilson et al., 2011).
Eikelenboom et al. (2011) suggest that late-onset Alzheimer's disease is a multifactorial disease based on the interaction between environmental factors and susceptible genes. Various environmental factors are known to induce acute and chronic systemic inflammation, which is associated with increased cognitive decline (Eikelenboom et al., 2011). Suspect environmental factors include surgical intervention, infection, traumatic brain injury, and vascular problems. Recent studies in genetics, epidemiology, and neuropathology suggest that innate immunity is an element of late-onset AD etiology (Eikelenboom et al., 2011). For example, studies of offspring of parents with late-onset AD suggest that a proinflammatory genotype with the capacity to produce higher levels of proinflammatory cytokines acts as a genetic risk factor for AD (Eikelenboom et al., 2011).
Alzheimer's disease is characterized by four stages: early, middle, middle-to-late, and final (Buckley & Schub, 2012). The onset of the disease is typically noticed by family members during the early stage, when the patient begins to exhibit mild depression, some difficulty learning, and a progressive loss of intellectual ability (Buckley & Schub, 2012). During the middle stage, the patient exhibits increased moodiness and other personality changes, social withdrawal, disorganized conversation, increased memory loss, and a decreased ability to perform activities of daily living (Buckley & Schub, 2012).
In the middle-to-late stage, the patient is significantly dependent on others to complete daily living activities, may wander, is incontinent, needs repeated instructions for simple tasks, is unable to recognize objects or family members, and has periodic outbursts of hostility, anger, and paranoia (Buckley & Schub, 2012). In the final stage, the patient has profound memory loss, cannot speak, cannot walk, has dysphagia, is bedridden, and may develop ulcers, contractures, respiratory failure, and/or pneumonia (Buckley & Schub, 2012).
"Amyloid oligomers, plaques, and candidate gene associations"
"White and gray matter damage in early vs. late onset"
"Approved drugs and investigational disease-modifying therapies"
"Inflammation, treatment timing, and promising therapies"
Always verify citation format against your institution’s current style guide requirements.